Back to search

Peptide record

TPDB92195

Hecate KAL V Antibacterial Anticancer Antifungal Antiviral Toxicity standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92195
Hecate KAL V
Antibacterial Anticancer Antifungal Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF Antifungipept CAFPdb dbAMP AVPpred-BWR
standard
No
A 23-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
VALALKALKKALKKLKKALKKAL-NH2
Physicochemical Analysis
C119H226N32O24
RNDCEQGHIMFPSTWY
K
2489.30
11.41
9
0
14
+9
4.04
0.283
157.39
Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
0
Residue Composition
number
6
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
7
L
9
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 6 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 7 K: 9 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
23
C119H226N32O24
2489.30
11.41
+9
4.04
0.283
Amidation
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 9 records
Evidence 1 Activity

Activity

LD50
LD50 =72 µg/ml
Anticancer
72 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =340 µg/ml
Anticancer
340 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =62 µg/ml
Anticancer
62 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

Not Available
Anticancer

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =140 µg/ml
Anticancer
140 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

Not Available
Anticancer

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 7 Activity

Activity

LD50
LD50 =125 µg/ml
Anticancer
125 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 8 Activity

Activity

LD50
LD50 =65 µg/ml
Anticancer
65 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 9 Activity

Activity

LD50
LD50 =190 µg/ml
Anticancer
190 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2